{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:51:23Z","timestamp":1793962283289,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"F. Hoffman La-Roche Ltd. There is no grant number"},{"name":"F. Hoffman La-Roche Ltd. There is no grant number."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with macular pathology, including that caused by age-related macular degeneration and diabetic macular oedema, must attend frequent in-clinic monitoring appointments to detect onset of disease activity requiring treatment and to monitor progression of existing disease. In-person clinical monitoring places a significant burden on patients, caregivers and healthcare systems and is limited in that it only provides clinicians with a snapshot of the patient\u2019s disease status. The advent of remote monitoring technologies offers the potential for patients to test their own retinal health at home in collaboration with clinicians, reducing the need for in-clinic appointments. In this review we discuss visual function tests, both existing and novel, that have the potential for remote use and consider their suitability for discriminating the presence of disease and progression of disease. We then review the clinical evidence supporting the use of mobile applications for monitoring of visual function from clinical development through to validation studies and real-world implementation. This review identified seven app-based visual function tests: four that have already received some form of regulatory clearance and three under development. The evidence included in this review shows that remote monitoring offers great potential for patients with macular pathology to monitor their condition from home, reducing the need for burdensome clinic visits and expanding clinicians\u2019 understanding of patients\u2019 retinal health beyond traditional clinical monitoring. In order to instil confidence in the use of remote monitoring in both patients and clinicians further longitudinal real-world studies are now warranted.<\/jats:p>","DOI":"10.1038\/s41433-023-02479-y","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:03:09Z","timestamp":1679922189000},"page":"3108-3120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Home vision monitoring in patients with maculopathy: current and future options for digital technologies"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7690-6277","authenticated-orcid":false,"given":"Konstantinos","family":"Balaskas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Drawnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mavromaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"2479_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"2479_CR2","first-page":"S3","volume":"24","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24:S3\u2013S15.","journal-title":"J Manag Care Spec Pharm"},{"key":"2479_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica"},{"key":"2479_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ophtha.2011.10.019","volume":"119","author":"DV Do","year":"2012","unstructured":"Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, et al. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC study. Ophthalmology. 2012;119:771\u20138.","journal-title":"Ophthalmology"},{"key":"2479_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jamaophthalmol.2019.1947","volume":"137","author":"R Parikh","year":"2019","unstructured":"Parikh R, Avery RL, Saroj N, Thompson D, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab. JAMA Ophthalmol. 2019;137:914\u201320.","journal-title":"JAMA Ophthalmol"},{"key":"2479_CR6","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","volume":"26","author":"TA Ciulla","year":"2003","unstructured":"Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26:2653\u201364.","journal-title":"Diabetes Care"},{"key":"2479_CR7","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41433-020-0895-z","volume":"34","author":"AP Adamis","year":"2020","unstructured":"Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye. 2020;34:1966\u201372.","journal-title":"Eye"},{"key":"2479_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","volume":"204","author":"TJ Wubben","year":"2019","unstructured":"Wubben TJ, Johnson MW. Anti-vascular endothelial growth factor therapy for diabetic retinopathy: Consequences of inadvertent treatment interruptions. Am J Ophthalmol. 2019;204:13\u201318.","journal-title":"Am J Ophthalmol"},{"key":"2479_CR9","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017;37:2254\u201361.","journal-title":"Retina"},{"key":"2479_CR10","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4:e000398.","journal-title":"BMJ Open Ophthalmol"},{"key":"2479_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12652-017-0598-x","volume":"10","author":"LP Malasinghe","year":"2019","unstructured":"Malasinghe LP, Ramzan N, Dahal K. Remote patient monitoring: a comprehensive study. J Ambient Intell Humaniz Comput. 2019;10:57\u201376.","journal-title":"J Ambient Intell Humaniz Comput"},{"key":"2479_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/tmj.2016.0051","volume":"23","author":"A Vegesna","year":"2017","unstructured":"Vegesna A, Tran M, Angelaccio M, Arcona S. Remote patient monitoring via non-invasive digital technologies: a systematic review. Telemed J E Health. 2017;23:3\u201317.","journal-title":"Telemed J E Health"},{"key":"2479_CR13","unstructured":"Pew Research Center. Mobile fact sheet. 2021. https:\/\/www.pewresearch.org\/internet\/fact-sheet\/mobile\/ (Accessed 02 February 2022)."},{"key":"2479_CR14","unstructured":"Statista.com. Share of adults who own a smartphone in the United Kingdom (UK) in 2008 and 2019 to 2020, by demographics. 2020. https:\/\/www.statista.com\/statistics\/956297\/ownership-of-smartphones-uk\/ (Accessed 02 February 2022)."},{"key":"2479_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/10400435.2019.1682084","volume":"34","author":"N Martiniello","year":"2019","unstructured":"Martiniello N, Eisenbarth W, Lehane C, Johnson A, Wittich W. Exploring the use of smartphones and tablets among people with visual impairments: Are mainstream devices replacing the use of traditional visual aids? Assist Technol. 2019;34:34\u201345.","journal-title":"Assist Technol"},{"key":"2479_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3928\/23258160-20160229-08","volume":"47","author":"C Ludwig","year":"2016","unstructured":"Ludwig C, Callaway N, Ho Park J, Leng T. Mobile health in the retinal clinic population: access to and interest in self-tracking. Ophthalmic Surg Lasers Imaging Retin. 2016;47:252\u20137.","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"2479_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41433-020-01263-6","volume":"35","author":"R Chopra","year":"2021","unstructured":"Chopra R, Wagner SK, Keane PA. Optical coherence tomography in the 2020s\u2014outside the eye clinic. Eye. 2021;35:236\u201343.","journal-title":"Eye"},{"key":"2479_CR18","doi-asserted-by":"publisher","unstructured":"Liu Y, Holekamp NLM, Heier JS. Prospective, longitudinal study: daily self- imaging with home OCT in neovascular age-related macular degeneration. Ophthalmol Retina. 2022;S2468-6530 (2422)00073-00072. https:\/\/doi.org\/10.1016\/j.oret.2022.02.011.","DOI":"10.1016\/j.oret.2022.02.011"},{"key":"2479_CR19","first-page":"21","volume":"12","author":"JM Charlesworth","year":"2019","unstructured":"Charlesworth JM, Davidson MA. Undermining a common language: smartphone applications for eye emergencies. Med Devices (Auckl). 2019;12:21\u201340.","journal-title":"Med Devices (Auckl)"},{"key":"2479_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaophthalmol.2020.6177","volume":"139","author":"BJ Steren","year":"2021","unstructured":"Steren BJ, Young B, Chow J. Visual acuity testing for telehealth using mobile applications. JAMA Ophthalmol. 2021;139:344\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"2479_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41746-019-0154-5","volume":"2","author":"WK Yeung","year":"2019","unstructured":"Yeung WK, Dawes P, Pye A, Charalambous A-P, Neil M, Aslam T, et al. eHealth tools for the self-testing of visual acuity: a scoping review. NPJ Digit Med. 2019;2:82.","journal-title":"NPJ Digit Med"},{"key":"2479_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3928\/23258160-20160808-03","volume":"47","author":"JS Chen","year":"2016","unstructured":"Chen JS, Adelman RA. Hyperacuity exam screens for choroidal neovascularization in age-related macular degeneration on a mobile device. Ophthalmic Surg Lasers Imaging Retin. 2016;47:708\u201315.","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"2479_CR23","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41433-019-0455-6","volume":"33","author":"MK Schmid","year":"2019","unstructured":"Schmid MK, Thiel MA, Lienhard K, Schlingemann RO, Faes L, Bachmann LM. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration. Eye. 2019;33:1584\u20139.","journal-title":"Eye"},{"key":"2479_CR24","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1167\/iovs.13-12037","volume":"54","author":"Y-Z Wang","year":"2013","unstructured":"Wang Y-Z, He Y-G, Mitzel G, Zhang S, Bartlett M. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci. 2013;54:5497\u2013505.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/aos.12659","volume":"93","author":"C Winther","year":"2015","unstructured":"Winther C, Fris\u00e9n L. New rarebit vision test captures macular deficits hidden to acuity tests. Acta Ophthalmol. 2015;93:481\u20135.","journal-title":"Acta Ophthalmol"},{"key":"2479_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1444-0938.2005.tb06713.x","volume":"88","author":"J Lovie-Kitchin","year":"2005","unstructured":"Lovie-Kitchin J, Feigl B. Assessment of age-related maculopathy using subjective vision tests. Clin Exp Optom. 2005;88:292\u2013303.","journal-title":"Clin Exp Optom"},{"key":"2479_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1475-1313.1998.97000434.x","volume":"18","author":"GM Ismail","year":"1998","unstructured":"Ismail GM, Whitaker D. Early detection of changes in visual function in diabetes mellitus. Ophthalmic Physiol Opt. 1998;18:3\u201312.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2479_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1444-0938.2003.tb03097.x","volume":"86","author":"EP Stavrou","year":"2003","unstructured":"Stavrou EP, Wood JM. Letter contrast sensitivity changes in early diabetic retinopathy. Clin Exp Optom. 2003;86:152\u20136.","journal-title":"Clin Exp Optom"},{"key":"2479_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0022-7","volume":"1","author":"R Schwartz","year":"2015","unstructured":"Schwartz R, Loewenstein A. Early detection of age related macular degeneration: current status. Int J Retin Vitreous. 2015;1:20.","journal-title":"Int J Retin Vitreous"},{"key":"2479_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/bjo.2006.095315","volume":"91","author":"M Crossland","year":"2007","unstructured":"Crossland M, Rubin G. The Amsler chart: absence of evidence is not evidence of absence. Br J Ophthalmol. 2007;91:391\u20133.","journal-title":"Br J Ophthalmol"},{"key":"2479_CR31","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/OPX.0000000000000324","volume":"91","author":"L Liu","year":"2014","unstructured":"Liu L, Wang Y-Z, Bedell HE. Visual-function tests for self-monitoring of age- related macular degeneration. Optom Vis Sci. 2014;91:956\u201365.","journal-title":"Optom Vis Sci"},{"key":"2479_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/eye.2014.104","volume":"28","author":"L Faes","year":"2014","unstructured":"Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye. 2014;28:788\u201396.","journal-title":"Eye"},{"key":"2479_CR33","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archopht.1993.01090060064024","volume":"111","author":"RA Schuchard","year":"1993","unstructured":"Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol. 1993;111:776\u201380.","journal-title":"Arch Ophthalmol"},{"key":"2479_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archopht.1986.01050160069013","volume":"104","author":"AM Fine","year":"1986","unstructured":"Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol. 1986;104:513\u20134.","journal-title":"Arch Ophthalmol"},{"key":"2479_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/OPTH.S59012","volume":"9","author":"PA Keane","year":"2015","unstructured":"Keane PA, de Salvo G, Sim DA, Goverdhan S, Agrawal R, Tufail A. Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. Clin Ophthalmol. 2015;9:353\u201366.","journal-title":"Clin Ophthalmol"},{"key":"2479_CR36","first-page":"503","volume":"18","author":"FH Zaidi","year":"2004","unstructured":"Zaidi FH, Cheong-Leen R, Gair EJ, Weir R, Sharkawi E, Lee N, et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. West Lond Surv Eye. 2004;18:503\u20138.","journal-title":"West Lond Surv Eye"},{"key":"2479_CR37","first-page":"469","volume":"38","author":"E Midena","year":"1997","unstructured":"Midena E, Degli Angeli C, Blarzino MC, Valenti M, Segato T. Macular function impairment in eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:469\u201377.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR38","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1167\/iovs.02-0769","volume":"44","author":"JA Phipps","year":"2003","unstructured":"Phipps JA, Guymer RH, Vingrys AJ. Loss of cone function in age-related maculopathy. Invest Ophthalmol Vis Sci. 2003;44:2277\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000310612","volume":"209","author":"N Stangos","year":"1995","unstructured":"Stangos N, Voutas S, Topouzis F, Karampatakis V. Contrast sensitivity evaluation in eyes predisposed to age-related macular degeneration and presenting normal visual acuity. Ophthalmologica. 1995;209:194\u20138.","journal-title":"Ophthalmologica"},{"key":"2479_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0042-6989(77)90206-1","volume":"17","author":"G Westheimer","year":"1977","unstructured":"Westheimer G, McKee SP. Integration regions for visual hyperacuity. Vis Res. 1977;17:89\u201393.","journal-title":"Vis Res"},{"key":"2479_CR41","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/0042-6989(77)90069-4","volume":"17","author":"G Westheimer","year":"1977","unstructured":"Westheimer G, McKee SP. Spatial configurations for visual hyperacuity. Vis Res. 1977;17:941\u20137.","journal-title":"Vis Res"},{"key":"2479_CR42","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1016\/S0042-6989(98)00039-X","volume":"38","author":"F Wilkinson","year":"1998","unstructured":"Wilkinson F, Wilson HR, Habak C. Detection and recognition of radial frequency patterns. Vis Res. 1998;38:3555\u201368.","journal-title":"Vis Res"},{"key":"2479_CR43","first-page":"2055","volume":"43","author":"YZ Wang","year":"2002","unstructured":"Wang YZ, Wilson E, Locke KG, Edwards AO. Shape discrimination in age- related macular degeneration. Invest Ophthalmol Vis Sci. 2002;43:2055\u201362.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.22599\/bioj.89","volume":"12","author":"N Pitrelli Vazquez","year":"2015","unstructured":"Pitrelli Vazquez N, Knox PC. Assessment of visual distortions in age-related macular degeneration: emergence of new approaches. Br Ir Orthopt J. 2015;12:9\u201315.","journal-title":"Br Ir Orthopt J"},{"key":"2479_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00006324-200106000-00019","volume":"78","author":"Y-Z Wang","year":"2001","unstructured":"Wang Y-Z. Effects of aging on shape discrimination. Optom Vis Sci. 2001;78:447\u201354.","journal-title":"Optom Vis Sci"},{"key":"2479_CR46","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0042-6989(02)00102-5","volume":"42","author":"L Fris\u00e9n","year":"2002","unstructured":"Fris\u00e9n L. New, sensitive window on abnormal spatial vision: rarebit probing. Vis Res. 2002;42:1931\u20139.","journal-title":"Vis Res"},{"key":"2479_CR47","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/bjo.2007.124461","volume":"91","author":"M Nilsson","year":"2007","unstructured":"Nilsson M, von Wendt G, Wanger P, Martin L. Early detection of macular changes in patients with diabetes using Rarebit Fovea Test and optical coherence tomography. Br J Ophthalmol. 2007;91:1596\u20138.","journal-title":"Br J Ophthalmol"},{"key":"2479_CR48","doi-asserted-by":"publisher","unstructured":"Winther C, Fris\u00e9n L. Self-testing of vision in age-related macula degeneration: A longitudinal pilot study using a smartphone-based rarebit test. J Ophthalmol. 2015:285463. https:\/\/doi.org\/10.1155\/2015\/285463.","DOI":"10.1155\/2015\/285463"},{"key":"2479_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40123-019-0203-9","volume":"8","author":"J Brucker","year":"2019","unstructured":"Brucker J, Bhatia V, Sahel J-A, Girmens J-F, Mohand-Sa\u00efd S. Odysight: a mobile medical application designed for remote monitoring\u2014a prospective study comparison with standard clinical eye tests. Ophthalmol Ther. 2019;8:461\u201376.","journal-title":"Ophthalmol Ther"},{"key":"2479_CR50","first-page":"6","volume":"2","author":"A Nikam","year":"2020","unstructured":"Nikam A, Lefumat H, Grondin E, Bhatia V. OdySight: real-world data analysis of a mobile medical application for ophthalmology. J Ophthalmol Sci. 2020;2:6\u201312.","journal-title":"J Ophthalmol Sci"},{"key":"2479_CR51","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajo.2021.03.033","volume":"227","author":"RN Khurana","year":"2021","unstructured":"Khurana RN, Hoang C, Khanani AM, Steklov N, Singerman LJ. A smart mobile application to monitor visual function in diabetic retinopathy and age-related macular degeneration: The CLEAR study. Am J Ophthalmol. 2021;227:222\u201330.","journal-title":"Am J Ophthalmol"},{"key":"2479_CR52","doi-asserted-by":"publisher","unstructured":"Wu Z, Guymer RH, Jung CJ, Goh JK, Ayton LN, Luu CD, et al. Measurement of retinal sensitivity on tablet devices in age-related macular degeneration. Transl Vis Sci Technol. 2015;4. https:\/\/doi.org\/10.1167\/tvst.1164.1163.1113.","DOI":"10.1167\/tvst.1164.1163.1113"},{"key":"2479_CR53","doi-asserted-by":"publisher","unstructured":"Ho CYD, Wu Z, Turpin A, Lawson DJ, Luu C, McKendrick A, et al. A tablet- based retinal function test in neovascular age-related macular degeneration eyes and at-risk fellow eye. Transl Vis Sci Technol. 2018;7. https:\/\/doi.org\/10.1167\/tvst.1167.1162.1162.","DOI":"10.1167\/tvst.1167.1162.1162"},{"key":"2479_CR54","unstructured":"Food and Drug Administration. 510(k) summary: K121738 2012. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf12\/K121738.pdf (Accessed 02 February 2022)."},{"key":"2479_CR55","doi-asserted-by":"publisher","first-page":"e2650","DOI":"10.7717\/peerj.2650","volume":"4","author":"JY Ku","year":"2016","unstructured":"Ku JY, Milling AF, Pitrelli Vazquez N, Knox PC. Performance, usability and comparison of two versions of a new macular vision test: the handheld Radial Shape Discrimination test. PeerJ. 2016;4:e2650.","journal-title":"PeerJ"},{"key":"2479_CR56","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/IAE.0b013e3182899258","volume":"33","author":"PK Kaiser","year":"2013","unstructured":"Kaiser PK, Wang YZ, He YG, Weisberger A, Wolf S, Smith CH. Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study. Retina. 2013;33:1863\u201370.","journal-title":"Retina"},{"key":"2479_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jamaophthalmol.2021.5269","volume":"140","author":"E Korot","year":"2022","unstructured":"Korot E, Pontikos N, Drawnel FM, Jaber A, Fu DJ, Zhang G, et al. Enablers and barriers to deployment of smartphone-based home vision monitoring in clinical practice settings. JAMA Ophthalmol. 2022;140:153\u201360.","journal-title":"JAMA Ophthalmol"},{"key":"2479_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/09286586.2020.1793371","volume":"28","author":"LA Lott","year":"2021","unstructured":"Lott LA, Schneck ME, Haegerstrom-Portnoy G, Hewlett S, Stepien-Bernabe N, Gauer BM, et al. Simple vision function tests that distinguish eyes with early to intermediate age-related macular degeneration. Ophthalmic Epidemiol. 2021;28:93\u2013104.","journal-title":"Ophthalmic Epidemiol"},{"key":"2479_CR59","doi-asserted-by":"publisher","first-page":"e0207342","DOI":"10.1371\/journal.pone.0207342","volume":"13","author":"N Pitrelli Vazquez","year":"2018","unstructured":"Pitrelli Vazquez N, Harding SP, Heimann H, Czanner G, Knox PC. Radial shape discrimination testing for new-onset neovascular age-related macular degeneration in at-risk eyes. PLoS One. 2018;13:e0207342.","journal-title":"PLoS One"},{"key":"2479_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/OPX.0000000000001624","volume":"98","author":"ME Schneck","year":"2021","unstructured":"Schneck ME, Lott LA, Haegerstrom-Portnoy G, Hewlett S, Gauer BM, Zaidi A. Visual function in eyes with intermediate AMD with and without retinal pigment abnormalities. Optom Vis Sci. 2021;98:64\u201372.","journal-title":"Optom Vis Sci"},{"key":"2479_CR61","first-page":"516","volume":"56","author":"Y-Z Wang","year":"2015","unstructured":"Wang Y-Z, He Y-G, Csaky KG, Mitzel G, Hernandez K, Zhang S, et al. Diabetic retinopathy and the myVisionTrack\u00ae app (DRAMA) study. Invest Ophthalmol Vis Sci. 2015;56:516.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR62","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1167\/iovs.14-14793","volume":"55","author":"Y-Z Wang","year":"2014","unstructured":"Wang Y-Z, He Y-G, Mitzel G, Zhang S, Bartlett MB. Compliance and test variability of patients with maculopathy in using an iphone-based shape discrimination hyperacuity test at home. Invest Ophthalmol Vis Sci. 2014;55:5602.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR63","first-page":"5019","volume":"54","author":"Y-Z Wang","year":"2013","unstructured":"Wang Y-Z, Mitzel G. A new contour integration macular perimetry (CIMP) on iPad for visual function evaluation in maculopathy. Invest Ophthalmol Vis Sci. 2013;54:5019.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR64","first-page":"100","volume":"52","author":"Y-Z Wang","year":"2011","unstructured":"Wang Y-Z, Ying G-S, Mitzel G, He Y-G. Sensitivity and specificity of shape discrimination hyperacuity for differentiating exudative AMD from moderate AMD. Invest Ophthalmol Vis Sci. 2011;52:100.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR65","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41433-020-0910-4","volume":"35","author":"E Ward","year":"2021","unstructured":"Ward E, Wickens RA, O\u2019Connell A, Culliford LA, Rogers CA, Gidman EA, et al. Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study. Eye. 2021;35:592\u2013600.","journal-title":"Eye"},{"key":"2479_CR66","first-page":"1245","volume":"5","author":"KY Chong Teo","year":"2021","unstructured":"Chong Teo KY, Bachmann LM, Sim D, Yen LS, Tan A, Wong TY, et al. Patterns and characteristics of a real-world implementation of a self-monitoring program for retina diseases during COVID-19 pandemic. Ophthalmol. Retina. 2021;5:1245\u201353.","journal-title":"Retina"},{"key":"2479_CR67","first-page":"11","volume":"16","author":"RA Gangwani","year":"2012","unstructured":"Gangwani RA, Leung CK, Lam PT. Full correction of refractive errors during automated perimetry: does it really matter? Hong Kong. J Ophthalmol. 2012;16:11\u201313.","journal-title":"J Ophthalmol"},{"key":"2479_CR68","doi-asserted-by":"publisher","first-page":"580","DOI":"10.18240\/ijo.2020.04.08","volume":"13","author":"C Zhao","year":"2020","unstructured":"Zhao C, Cun Q, Tao Y-J, Yang W-Y, Zhong H, Li F-J, et al. Effect of intraocular lens implantation on visual field in glaucoma and comorbid cataracts. Int J Ophthalmol. 2020;13:580\u20136.","journal-title":"Int J Ophthalmol"},{"key":"2479_CR69","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.cct.2014.02.003","volume":"37","author":"EY Chew","year":"2014","unstructured":"Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design \u2014 HOME Study report number 1. Contemp Clin Trials. 2014;37:294\u2013300.","journal-title":"Contemp Clin Trials"},{"key":"2479_CR70","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.3390\/ijerph192013714","volume":"19","author":"SR O\u2019Connor","year":"2022","unstructured":"O\u2019Connor SR, Treanor C, Ward E, Wickens RA, O\u2019Connell A, Culliford LA, et al. Patient acceptability of home monitoring for neovascular age-related macular degeneration reactivation: a qualitative study. Int J Environ Res Public Health. 2022;19:13714.","journal-title":"Int J Environ Res Public Health"},{"key":"2479_CR71","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","volume":"126","author":"PA Campochiaro","year":"2019","unstructured":"Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: Results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019;126:1141\u201354.","journal-title":"Ophthalmology"},{"key":"2479_CR72","first-page":"2295","volume":"61","author":"S Ellis","year":"2020","unstructured":"Ellis S, Buchberger A, Holder J, Orhan E, Hughes J. GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2020;61:2295.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2479_CR73","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: The STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964\u201372.","journal-title":"JAMA Ophthalmol"},{"key":"2479_CR74","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","volume":"5","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Callanan D, Dreyer R, Chen S, Howard JG, Hopkins JJ, et al. End-of-study results for the Ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retin. 2021;5:775\u201387.","journal-title":"Ophthalmol Retin"},{"key":"2479_CR75","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"2479_CR76","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ajo.2019.01.005","volume":"200","author":"RN Khurana","year":"2019","unstructured":"Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, et al. Extended (every 12 weeks or longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of view trials. Am J Ophthalmol. 2019;200:161\u20138.","journal-title":"Am J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02479-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02479-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02479-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:06:49Z","timestamp":1696932409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02479-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":76,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2479"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02479-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KB has served as a consultant for Roche and Novartis and has received speaker fees from Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis and Topcon. FD is an employee of, and holds stock in, F. Hoffmann-La Roche Ltd. AMK has served as a consultant for Adverum, Aerpio, Alimera, Allergan, Apellis, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, 4DMT, Dutch Ophthalmic Research Centre, Gemini, Genentech, Glaukos, Graybug Vision, Gyroscope, Iveric Bio, Janssen, Kato Pharma, Kodiak, Oculis, Opthea, Oxurion, Novartis, Polyphotonix, Recens Medical, Regeneron, Retrotope, Regenxbio, Roche, Surrozen, Thea and Unity Bio; has received research support from Adverum, Apellis, Asclepix, Chengdu Kanghong, 4DMT, Gemini, Genentech, Graybug Vision, Gyroscope, Iveric Bio, Janssen, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio; and has received speaker fees from Allergan, Genentech and Novartis. PCK had a research agreement with Vital Art & Science Inc. At the time of writing, GM was an employee of Genentech Inc. and acted as the Lead Product Manager for Home Vision Monitor\u00ae app. Before joining Genentech Inc., GM was the Chief Marketing Officer (CMO) for myVisionTrack\u00ae, later acquired by Roche\/Genentech Inc. Y-ZW has served as a consultant for Genentech, Inc. and Roche, and has patents on mobile visual function testing technology. The funder, F. Hoffmann-La Roche Ltd., is the owner of one of the apps identified in this review (Home Vision Monitor, previously myVisionTrack\u00ae). To avoid bias, the authors independently determined the scope of the literature search and developed the search criteria. Equal consideration was given to all literature identified in the search. F. Hoffmann-La Roche Ltd. reviewed the manuscript before submission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}